EXAMINATION OF SOME MOLECULES IN PLACENTAS OF PATIENTS WITH PLACENTA PREVIA, PLACENTA PERCREATA

Launched by CELAL BAYAR UNIVERSITY · Feb 22, 2025

Keywords

ClinConnect Summary

This clinical trial is looking into certain molecules found in the placentas of pregnant women who have conditions called placenta previa and placenta percreta. Placenta previa can cause serious bleeding during labor, while placenta percreta is when the placenta grows too deeply into the uterine wall, which can also lead to complications after delivery. The study aims to understand how levels of specific molecules in the placenta may be linked to these conditions. This research is important because it can help improve the management of these pregnancies and reduce risks for both mothers and their babies.

To participate in this study, women must be between the ages of 18 and 50, have a healthy pregnancy under 37 weeks, and be able to read and understand Turkish. They should not have any high-risk pregnancy issues or ongoing health problems. Those who join will have their placentas studied to help scientists learn more about these conditions. If you're interested in this trial or think you might qualify, it could be a valuable opportunity to contribute to important research that may benefit others in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy pregnancy under 37 weeks
• • Age range 18-50
• • Being literate in Turkish
• • Not having any additional disease
• • Agreeing to participate in the study
• Exclusion Criteria:
• • High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.)
• • Multiple pregnancy
• • Pregnant women under the age of 18
• • Smoking
• • Medication use (excluding routinely used food supplements during pregnancy)
• • Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.)
• • Immunosuppressive use
• • Presence of active or chronic infection
• • Presence of active or chronic inflammatory disease
• • Patients who gave birth at an external center or later chose to withdraw from the study
• • Patients who did not have any exclusion criteria at the time of Placenta percrata/ placenta previa or when blood was drawn for the control group, but who later developed any exclusion criteria.
• • Premature birth of patients included in the control group